Inclusion Criteria:

- Histologically or cytologically confirmed soft-tissue sarcoma*

- Unresectable disease

- Locally recurrent or metastatic disease

- Disease amenable to biopsy (patients treated at the maximum tolerated dose only)

- No known prior or concurrent brain metastases

- Performance status - Karnofsky 60-100%

- Performance status - ECOG 0-2

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Bilirubin ≤ 1.5 mg/dL

- AST and ALT ≤ 2.5 times upper limit of normal

- Creatinine ≤ 1.5 mg/dL

- Creatinine clearance ≥ 60 mL/min

- Ejection fraction ≥ 50% by MUGA or echocardiogram

- No uncontrolled hypertension

- No myocardial infarction

- No New York Heart Association class II-IV congestive heart failure

- No unstable angina

- No serious cardiac arrhythmia requiring medication

- No peripheral vascular disease ≥ grade 2 within the past year

- No other clinically significant cardiac disease

- No prior deep vein thrombosis

- No other prior vascular thrombus

- No prior pulmonary embolism

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No symptomatic peripheral neuropathy ≥ grade 2

- No other malignancy within the past 5 years except adequately treated basal cell skin
cancer or carcinoma in situ of the cervix

- Carcinoma in situ not considered a second malignancy

- No history of allergic reaction attributed to compounds of similar chemical or
biologic composition to study drugs

- No psychiatric illness or social situation that would preclude study compliance

- No ongoing or active infection

- No other uncontrolled illness

- See Chemotherapy

- At least 3 weeks since prior immunotherapy and recovered

- At least 3 weeks since prior chemotherapy (6 weeks for carmustine or mitomycin) and
recovered

- No more than 2 prior cytotoxic chemotherapy regimens

- Peroxisome proliferator-activated receptor (PPAR)-gamma agonists, thalidomide,
or targeted therapy (i.e., tyrosine kinase inhibitors including imatinib
mesylate, sorafenib, or sunitinib malate) do not count as a prior chemotherapy
regimen

- No prior anthracyclines

- At least 3 weeks since prior radiotherapy and recovered

- No prior extensive radiotherapy to bone marrow-producing sites (e.g., radiotherapy to
both the pelvis and spine)

- At least a 1 week washout period since prior tyrosine kinase inhibitors or other
targeted therapy

- Concurrent low-dose warfarin (1 mg per day) to prevent thrombus of a central line
allowed

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent investigational agents

- No other concurrent anticancer therapy